Success Metrics

Active Trials
1(33%)

Phase Distribution

Ph phase_1
2
67%
Ph phase_2
1
33%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(2)
Other(1)

Detailed Status

Recruiting1
unknown1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 12 (66.7%)
Phase 21 (33.3%)

Trials by Status

recruiting133%
unknown133%
not_yet_recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingphase_2

JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma

NCT06954467
not_yet_recruitingphase_1

Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

NCT06370754
unknownphase_1

Clinical Study of JS007 in Patients With Advanced Solid Tumors

NCT05049265

Clinical Trials (3)

Showing 3 of 3 trials
NCT06954467Phase 2

JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma

Recruiting
NCT06370754Phase 1

Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

Not Yet Recruiting
NCT05049265Phase 1

Clinical Study of JS007 in Patients With Advanced Solid Tumors

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3